drugset / Trial / NCT05320133

Jinghua Weikang Capsule Containing Quadruple Therapy for IgAN With Helicobacter Pylori Infection

NCT05320133

Unknown 80 enrolled Peking University First Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is to evaluate the efficacy and safety of the Jinghua Weikang Capsule (a Chinese patent medicine for peptic ulcer and gastritis) containing quadruple therapy (Jinghua Weikang Caplsule plus triple therpy) for eradicating Helicobacter pylori in IgA nephropathy.

Timeline

Start
2022-06-20
Primary completion
2024-11-30
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bismuth Potassium Citrate Unknown 220 mg
Subject Jinghua Weikang Capsule Traditional medicine (herbal / TCM) 240 mg
Background Clarithromycin Small molecule 500 mg
Background Rabeprazole Small molecule 10 mg
Background moxycillin Unknown 1 g